- Home
- ONCO
ONCO
Onconetix Inc.
as 12-18-2024 11:45am EST
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Upcoming Earnings Alert:
Get ready for potential market movements as Onconetix Inc. ONCO prepares to release earnings report on 24 Dec 2024.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 3.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 282.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -71.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $21.40 | Next Earning Date: | 12-24-2024 |
| Revenue: | $1,870,605 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Onconetix Inc. News
ONCO Breaking Stock News: Dive into ONCO Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
GlobeNewswire
2 months ago
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
GlobeNewswire
3 months ago
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
GlobeNewswire
3 months ago
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
GlobeNewswire
5 months ago
Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds
GlobeNewswire
5 months ago
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
GlobeNewswire
10 months ago
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
PR Newswire
a year ago
CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS
Compare ONCO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONCO Onconetix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.